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Abstract
Background: Intravenously administered iodine-containing contrast medium (CM) is associated with the
development of contrast-induced nephropathy (CIN). Data on the effectiveness of sodium bicarbonate therapy in
the prevention of CIN are controversial. Furthermore, the incidence of and risk factors for CIN in intensive care unit
(ICU) patients are poorly defined. We investigated the effectiveness of sodium bicarbonate prophylaxis and the
incidence of and risk factors for CIN in a heterogeneous ICU population.
Methods: This retrospective cohort study included patients admitted to the ICU in 2009–2011 who received CM for
computed tomography (CT).
Results: Two hundred eleven CT scans with CM, performed in 170 patients, were included in the study. Contrast
prophylaxis with sodium bicarbonate was administered in 48 of the 211 cases. CIN developed in 19 of the
48 cases receiving prophylaxis and in 39 of 163 cases not receiving prophylaxis (p = 0.03). In 115 CTs performed in
patients with a glomerular filtration rate (GFR) >60 mL/min, prophylaxis was administered 15 times (13 %) and no
prophylaxis was administered 100 times (87 %). CIN developed in 12 and 13 % of these cases, respectively (NS). In
96 CTs in patients with a GFR <60 mL/min, 17 of 33 (51.5 %) cases receiving prophylaxis developed CIN and 27 of
63 (42.9 %) cases not receiving prophylaxis developed CIN (NS). Prophylactic sodium bicarbonate therapy did not
prevent CIN in our patients, irrespective of pre-existing renal failure. Pre-existing renal impairment (odds ratio 4.41),
an elevated Acute Physiology and Chronic Health Evaluation (APACHE) IV score (odds ratio 1.02), and higher
haemoglobin levels (odds ratio 0.64) were significant and independent risk factors associated with the development
of CIN.
Conclusions: Prophylactic isotonic sodium bicarbonate was not associated with a decreased incidence of CIN in
ICU patients. Current sodium bicarbonate prophylaxis guidelines cannot be generalized to a heterogeneous ICU
population. Pre-existing renal impairment was associated with the highest CIN risk.
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Background
Depending on the nature and degree of a patient’s
comorbidities, the intravenous (IV) administration of io-
dinated contrast media (CM) is associated with the de-
velopment of contrast-induced nephropathy (CIN). The
incidence of CIN varies between 1 and 50 % depending
on patient population, baseline risk factors, and the cri-
teria by which it is defined [1–3]. The definition of CIN
includes an exposure to a contrast agent (iodinated
CM), an absolute and/or relative increase in serum cre-
atinine (sCr) compared to baseline values following ex-
posure to a contrast agent, a temporal relationship
between the rise in sCr and CM exposure, and the ex-
clusion of reasonable alternative explanations for renal
impairment [4]. CIN is the third most common cause of
hospital-acquired renal failure and accounts for approxi-
mately 11 % of renal failure cases [5]. Most research,
however, has been conducted in an outpatient cardiology
setting, and studies regarding CIN in intensive care unit
(ICU) populations are scarce and inconsistent. In previ-
ous studies in the ICU population, the incidence of CIN
has varied from 14 to 23 %, depending on the definition
of CIN used [6–8].
CIN is associated with poor short- and long-term out-
comes, including the need for renal replacement therapy
(RRT), a longer length of stay in the ICU, and a higher
mortality rate [6–9]. A case-matched study by Cely et al.
showed that changes in renal function are more likely to
be attributable to factors other than the contrast expos-
ure itself [10]. They concluded that persistent (>3 days)
renal impairment due to contrast exposure occurred in
<2 % of the studied population.
Renal dysfunction in ICU patients occurs according to
a multihit model, and most patients have more than one
risk factor for renal dysfunction. Reported risk factors
for developing CIN in the ICU include diabetes mellitus,
sepsis, anaemia, hypotension and hemodynamic failure,
administration of potentially nephrotoxic drugs, and
renal impairment prior to exposure to a contrast agent
[6, 8–10]. The scarcity of data regarding the effectiveness
of preventive procedures for CIN in critically ill patients
has led to a debate regarding the optimal prophylactic
therapy. Therefore, the aim of this study was to assess
the effectiveness of the prophylactic administration of an
isotonic sodium bicarbonate solution in preventing CIN
in a heterogeneous ICU population of patients undergo-
ing a computed tomography (CT) scan with IV CM.
Methods
Patient inclusion criteria and data collection
This was a single-site retrospective study in a teaching
hospital with a 16-bed general ICU. All ICU patients ad-
mitted between January 2009 and December 2011 who
received CM for CT imaging were included. Informed
consent could not be obtained and was not required by
the Ethic Review Board because of the retrospective
study design. Nonionic iso-osmolar CM was used in all
patients. Patients undergoing RRT at the time of CM ad-
ministration, patients who underwent a second CT scan
within 4 days of the index CT scan, or patients who died
within the 4 days following the CT scan were excluded.
Serum Cr was recorded daily. All patients were followed
for at least 4 days. In case of earlier death, the last avail-
able sCr was used.
The primary independent variable was the use of
prophylactic treatment. Other variables included the
mean sCr from 2 days prior to the index CT and the cu-
mulative fluid balance from 2 days prior to the CT scan.
Glomerular filtration rate (GFR) was calculated using
age and sCr. Our institution follows a standard protocol
for prophylactic treatment of patients at risk of CIN
(GFR < 60 mL/min or elevated sCr). The guidelines we
followed at the time of the study called for the adminis-
tration of sodium bicarbonate (8.4 %) 90 mL added to
glucose (5 %) 500 mL infused at a rate of 3 mL/kg/h for
1 h prior to CM infusion and at 1 mL/kg/h for 6 h after
CM infusion [11].
The primary endpoint was the effectiveness of prophy-
lactic therapy in the prevention of CIN. The secondary
endpoints were the incidence of CIN, defined as a rise of
≥44 μmol/L and/or a 25 % increase in baseline sCr
within 4 days of CM administration, and the identifica-
tion of potential risk factors for the development of CIN
in ICU patients. To study the effectiveness of prophylac-
tic therapy, results are presented separately for CT scans
in patients with GFR >60 mL/min and in patients with
GFR <60 mL/min.
Statistical analysis
Categorical variables were analysed using Pearson’s chi-
square test or Fisher’s exact test. A p value <0.05 was
considered statistically significant. Continuous variables
were analysed using an independent t test or Mann-
Whitney U test depending on the distribution of the
variable. Multivariate binary logistic regression analysis
was performed to assess the risk factors associated with
the development of CIN. Apart from prophylactic ther-
apy, all variables that differed significantly between CT
procedures in patients who did and did not develop CIN
when tested with univariate analysis were included in
the multivariate analysis. All analyses were performed




There were 358 CT scans eligible for inclusion. Of these,
140 CT procedures met the a priori exclusion criteria.
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Additionally, 7 procedures were excluded owing to miss-
ing sCr data following the CT scan. Therefore, 211 CT
procedures in 170 patients were included in the final
analysis. The baseline characteristics of the study popu-
lation are shown in Table 1. The mean patient age was
65.3 years (range, 27–88 years). Men comprised 59.2 %
(125) of the CT procedure patients, and 70.1 % of cases
(148) were non-surgical cases. The mean Acute Physi-
ology and Chronic Health Evaluation (APACHE) IV
score of all included CT procedures was 79.5 (the pre-
dicted in-hospital mortality was 35.6 %).
Outcomes
Overall, CIN occurred 58 times (27.5 %) (Table 2). Ninety-
six cases undergoing CT procedures had an increased risk
of developing acute kidney injury (AKI) before the index
CT based on a calculated GFR <60 mL/min. After CM ad-
ministration, kidney function remained stable in 52 cases
(54.2 %), while renal function deteriorated in the other 44
cases (45.8 %). Despite recommendations to administer
prophylactic therapy to high-risk patients (including patients
with impaired renal function), only 33 (34.4 %) of these 96
CT procedure cases received prophylactic therapy. Of these
33 cases, CIN developed in 17 cases (51.5 %) (Table 2). CIN
developed in 27 of the remaining 63 cases (65.6 %) in which
no prophylactic therapy was administered (42.9 %, p = 0.42).
RRT was necessary in 9 cases (9.3 %); 7 (7.3 %) of these
cases did not receive prophylactic therapy (p= 0.27).
One hundred fifteen cases had normal renal function
prior to CM administration based on a calculated GFR
>60 mL/min, and therefore, their risk of developing AKI
was surmised to be low. Fourteen (12.2 %) of these 115
cases developed CIN. Fifteen cases (13.0 %) with normal
renal function received prophylactic therapy; 2 (13.3 %)
of these cases developed CIN nevertheless (Table 2). Of
the 100 cases in which no prophylactic therapy was ad-
ministered, CIN developed 12 times (12.0 %) and RRT
was necessary in 3 (25.0 %) of these cases. The occur-
rence of CIN was not statistically different between pa-
tients with normal renal function undergoing CT scans
with or without prophylactic therapy (p = 1.00).
A comparison of the characteristics of those cases with
CIN vs. those without the development of CIN is
displayed in Table 3. Overall, 39 patients died. The mor-
tality rate was significantly higher in patients who de-
veloped CIN than in those who did not (37.0 vs. 6.3 %,
p < 0.01). Causes of death are shown in Table 4.
A multivariate logistic regression analysis identified pre-
existing renal impairment (GFR < 60 mL/min) (odds ratio
4.58, p < 0.01), a higher APACHE IV score (odds ratio
1.02, p = 0.02), and a reduced haemoglobin level below
6 mmol/L (odds ratio 0.64, p = 0.03) as independent risk
factors for CIN (Table 5). Single-dose aminoglycoside ad-
ministration revealed a strong trend towards an independ-
ent risk factor in our study (odds ratio 3.87, p = 0.05), but
the results did not reach a level of statistical significance.
Table 1 Baseline characteristics of the study population
Variable Total number of CT* scans (n = 211) No prophylaxis (n = 163) Prophylaxis (n = 48) p value
Male gender 125 (59.2 %) 99 (60.7 %) 26 (54.2 %) 0.42
Age (years) 65.3 (12.5) 64.3 (12.6) 68.6 (11.5) 0.04
Baseline sCr (μmol/L) 77.7 (71.5) 73.0 (53.0) 104.5 (134.0) <0.01
Baseline GFR$ (mL/min) 68.6 (37.9) 73.6 (38.4) 51.8 (31.0) <0.01
§APACHE II score 20.4 (8.3) 20.5 (8.5) 20.0 (7.5) 0.70
APACHE IV score 79.5 (30.1) 78.6 (31.6) 82.5 (24.4) 0.43
Predicted in-hospital mortality (%) 35.6 % (24.2 %) 34.4 (25.0) 39.8 (21.2 %) 0.18
SOFA# day 1 5.0 (6.0) 6.5 (5.0) 5.0 (5.0) 0.07
SOFA day 4 6.0 (5.0) 6.0 (7.0) 4.0 (5.0) 0.02
Comorbidities
Diabetes 32 (15.2 %) 31 (19.0 %) 1 (2.1 %) <0.01
Heart failure 11 (5.2 %) 6 (3.7 %) 5 (10.4 %) 0.09
Sepsis 56 (26.5 %) 42 (25.8 %) 14 (29.2 %) 0.64
Haemoglobin < 6 (mmol/L) 57 (27.0 %) 42 (25.8 %) 15 (31.3 %) 0.45
Fluid balance 2529 (4701) 2401 (4639) 3123 (5695) 0.54
Patients receiving norepinephrine 54 (25.6 %) 43 (26.4 %) 11 (22.9 %) 0.63
Patients receiving aminoglycosides 12 (5.7 %) 10 (6.1 %) 2 (4.2 %) 1.00
Dichotomous data are noted as the number of CT scans with the presence of the concerning variable in that group (percentage of the total number of CTs).
Continuous data are noted as the mean (standard deviation) or median (interquartile range)
*CT computed tomography, $GFR glomerular filtration rate, sCr serum creatinine level, §APACHE Acute Physiology and Chronic Health Evaluation,#SOFA Sequential
Organ Failure Assessment
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A positive fluid balance, no norepinephrine use, and
increased age were associated with the CIN group with
univariate analysis (p = 0.03, p = 0.01, and p < 0.01, re-
spectively). However, in the multivariate analysis, these
variables were not statistically significant independent risk
factors for the development of CIN.
Discussion
The main finding of this study was the lack of an associ-
ation between the administration of prophylactic iso-
tonic sodium bicarbonate infusion and the prevention of
CIN in ICU patients receiving a contrast agent for CT
imaging. These findings are similar to recent studies by
Au et al. [12] and Deek et al. [13].
A secondary endpoint of our study was the evaluation
of potential risk factors for the development of CIN in
ICU patients. Our findings indicate that pre-existing
renal impairment (GFR < 60 mL/min), a high APACHE
IV score, and haemoglobin are significant independent
risk factors for the development of CIN (p < 0.01, p =
0.02, p = 0.03, respectively). GFR was chosen for the as-
sessment of renal impairment in our study because base-
line sCr measurements were not always available and
because urinary output can decline due to other factors,
such as hypotension or hypovolemia. Additionally, gen-
erally accepted protocols recommend the use of prophy-
lactic therapy based on a GFR <60 mL/min.
Remarkably, patients with no apparent renal dysfunction
(GFR > 60 mL/min) are also at risk for CIN. It is not
known if prophylactic therapy can prevent CIN in these
patients. The number of CT procedures in our study was
too low to draw unequivocal conclusions, but our findings
indicate no correlation between pre-diagnostic bicarbon-
ate administration and CIN incidence.
Prophylactic bicarbonate therapy addresses radiographic
CM administration, which is only one possible risk factor
for the development of renal dysfunction. ICU patients
frequently develop renal dysfunction, even in the absence
of CM administration, and not all patients with pre-
existing renal dysfunction experienced further deterior-
ation of their renal function after contrast administration.
A multihit model may explain the lack of efficacy of
prophylactic therapy in the prevention of CIN. Heart fail-
ure, anaemia, sepsis, hypoxia, and medications can all
negatively affect kidney function. In our ICU patients, we
Table 2 Effectiveness of sodium bicarbonate prophylaxis for the prevention of contrast-induced nephropathy in cases with or without
pre-existing renal impairment
GFR > 60 mL/min (n = 115) GFR < 60 mL/min (n = 96)
No prophylaxis (n = 100) Prophylaxis (n = 15) p value No prophylaxis (n = 63) Prophylaxis (n = 33) p value
No CIN 88 (88.0 %) 13 (86.7 %) 1.00 36 (57.1 %) 16 (48.5 %) 0.42
CIN 12 (12.0 %) 2 (13.3 %) 27 (42.9 %) 17 (51.5 %)
RRT/CIN 3/12 (25.0 %) 0/2 (0.0 %) 1.00 7/27 (25.9 %) 2/17 (11.8 %) 0.27
Dichotomous data are noted as the number of CT scans with the presence of the concerning variable in that group (percentage of the total number of CT scans)
CIN contrast-induced nephropathy, RRT renal replacement therapy, GFR glomerular filtration rate
Table 3 Characteristics of patients who did or did not develop
contrast-induced nephropathy
No CIN CIN p value
Number of CT scans 153 (72.5 %) 58 (27.5 %)
Age (years) 64 (13) 69 (10) <0.01
Male gender 88 (57.5 %) 37 (63.8 %) 0.41
Diabetes mellitus 22 (14.4 %) 10 (17.2 %) 0.61
Heart failure 6 (3.9 %) 5 (8.6 %) 0.18
Sepsis 41 (26.8 %) 15 (25.9 %) 0.89
Baseline GFR < 60 mL/min 52 (34.0 %) 44 (75.9 %) <0.01
Haemoglobin (mmol/L) 6.6 (1.1) 6.2 (0.88) 0.01
APACHE II score 19.5 (7.9) 22.8 (8.9) <0.01
APACHE IV score 74.5 (29.1) 92.6 (28.9) <0.01
SOFA day 1 8.0 (7.0) 5.0 (4.0) <0.01
SOFA day 4 11.0 (6.0) 4.0 (3.0) <0.01
Fluid balance (mL/24 h) 2180 (4566) 3488 (7251) 0.03
Aminoglycoside (single-dose) use 5 (3.3 %) 7 (12.1 %) 0.02
Norepinephrine use 32 (20.9 %) 22 (37.9 %) 0.01
Prophylactic therapy 29 (19.0 %) 19 (32.8 %) 0.03
Dichotomous data are noted as the number of patients with the presence of
the concerning variable in that group (percentage of the entire population).
Continuous data are noted as the mean (standard deviation) or median
(interquartile range)
CIN contrast-induced nephropathy, CT computed tomography, GFR glomerular
filtration rate, APACHE Acute Physiology and Chronic Health Evaluation, SOFA
Sequential Organ Failure Assessment
Table 4 Causes of mortality
Cause Prophylaxis Total
Yes No
MODS 12 6 18
Sepsis 8 4 12
Respiratory insufficiency 3 0 3
Anoxic encephalopathy 2 0 2
Bleeding 2 0 2
Combined respiratory and cardiac failure 0 2 2
Total 27 12 39
MODS multiple organ dysfunction syndrome
No significant differences were found between patients with or
without prophylaxis
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found haemoglobin and APACHE scores independently
associated with CIN, and an additional insult, such as the
use of CM, may act synergistically with these other factors
to cause more overt AKI.
We believe that generally accepted protocols do not
apply to ICU patients who are exposed to multiple po-
tential risk factors for renal impairment. Another reason
for the lack of efficacy of prophylaxis in ICU patients
may be related to the timing or dosage of the contrast
agent. However, the amount of contrast used in our
study (80 mL) is comparable to the amount typically
used in coronary angiography patients. Although there is
no evidence to support the inferiority of sodium bicar-
bonate 8.4 % to sodium chloride 0.9 % as prophylactic
therapy in the prevention of CIN, the dose of bicarbon-
ate used for prophylaxis may potentially be too low to
counterbalance a contrast-induced kidney injury [14].
Moreover, the overall effectiveness of any prophylactic
effect of sodium bicarbonate or sodium chloride is still
under debate and the object of ongoing study [15–18].
The prevalence of diabetes was slightly different between
patients who received prophylactic therapy and those who
did not, and this confounding factor may have influenced
our findings. No other baseline factors were significantly
different between those receiving prophylactic therapy and
those who did not receive prophylactic therapy. However,
diabetes is not a known independent risk factor for the
development of CIN and was not identified as a potential
risk factor in our multivariate analysis. Nevertheless, other
hidden confounders may have influenced our results.
Aminoglycosides are strongly associated with renal
dysfunction, especially in patients with persistently high
through levels. In our study, the administration of even
a single dose of an aminoglycoside (3 mg/kg) appeared
to increase the risk of developing CIN; however, this risk
was of borderline statistical significance (p = 0.05).
Another secondary endpoint was to determine the inci-
dence of CIN. The incidence of CIN in our study was
27.5 %. We chose to use a relatively broad definition of
CIN. Instead of measuring sCr within 48 h, which is com-
monly used, we included measurements up to 96 h after
the administration of the contrast agent to ensure that
cases of late-onset CIN were not missed. The Kidney
Disease/Improving Global Outcomes (KDIGO) guidelines,
which were used to establish a definition for contrast-
induced acute kidney injury (CI-AKI), acknowledge the
fact that a consistent time course for the diagnosis of CIN
has yet to be determined. Studies have shown a rise in sCr
up to 5 days after contrast administration [19]. The higher
incidence of CIN found in our study may be due to the
different definitions of CIN used and/or to variations in
the patient population studied [20].
Limitations of our study include the sample’s size and
retrospective design. Owing to the relatively small number
of subjects, a reliable subgroup statistical analysis was not
possible. Regarding the study design, a prospective ran-
domized controlled trial is urgently needed but would be
challenging to perform because of comorbidities and tim-
ing implications including the time of diagnosis, time of
CT scanning, and timing of prophylactic therapy.
Conclusions
In our study, prophylactic therapy with sodium bicar-
bonate was not associated with the prevention of CIN.
Pre-existing renal impairment (GFR < 60 mL/min), a
high APACHE IV score at the time of admission, and
anaemia were significant risk factors for CIN. Aminogly-
coside use was a borderline statistically significant risk
factor (p = 0.05), but more research is needed. The inci-
dence of CIN in this study was 27.5 %, indicating that
CIN occurs frequently in ICU patients, even when renal
function appears normal. Continued studies to improve
methods of prophylaxis are required to improve the
short- and long-term outcomes for ICU patients.
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Table 5 Risk factors for contrast-induced nephropathy in intensive
care unit patients (multivariate logistic regression analysis)
Variable OR p value
Prophylactic pre- and post-hydration (Y/N) 1.32 0.49
GFR < 60 mL/min or >60 mL/min 4.41 <0.01
APACHE IV score (per increasing point) 1.02 0.02
Norepinephrine use (Y/N) 1.49 0.32
Aminoglycoside use (Y/N) 3.87 0.05
Fluid balance (per ml) 1.00 0.95
Haemoglobin (>mmol/L) 0.64 0.03
Age (/year) 1.02 0.37
All variables that differed significantly between the no CIN and the CIN groups
in a univariate test (Table 4) were included in the multivariate regression
analysis, except for the APACHE II score. This score is highly correlated with
APACHE IV and therefore was discarded from the multivariate analysis
GFR glomerular filtration rate, OR odds ratio, APACHE Acute Physiology and
Chronic Health Evaluation
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